FDA gives AstraZeneca extension on cancer drug application
AstraZeneca
11,988.00p
16:40 26/04/24
-0.32%
-38.00p
The US Food and Drug Administration has given AstraZeneca and MSD a three month extension to review a new drug application for its prostate cancer treatment Lynparza.
Dow Jones I.A.
38,239.66
04:30 15/10/20
n/a
n/a
FTSE 100
8,139.83
17:09 26/04/24
n/a
n/a
FTSE 350
4,470.09
16:59 26/04/24
n/a
n/a
FTSE All-Share
4,423.59
17:14 26/04/24
n/a
n/a
Merck & Co. Inc.
$131.20
10:59 26/04/24
0.37%
$0.48
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
0.10%
22.78
Both companies said they would continue to work with the FDA to facilitate the completion of the agency's review.